This report serves to describe the mutational landscape and properties of a given individual set, as well as rank genes and genesets according to mutational significance. MutSig v2.0 was used to generate the results found in this report.
-
Working with individual set: READ-TP
-
Number of patients in set: 69
The input for this pipeline is a set of individuals with the following files associated for each:
-
An annotated .maf file describing the mutations called for the respective individual, and their properties.
-
A .wig file that contains information about the coverage of the sample.
-
MAF used for this analysis:READ-TP.final_analysis_set.maf
-
Significantly mutated genes (q ≤ 0.1): 14
-
Mutations seen in COSMIC: 222
-
Significantly mutated genes in COSMIC territory: 10
-
Genes with clustered mutations (≤ 3 aa apart): 117
-
Significantly mutated genesets: 33
-
Significantly mutated genesets: (excluding sig. mutated genes):0
-
Read 38 MAFs of type "Broad"
-
Read 35 MAFs of type "Baylor-SOLiD"
-
Total number of mutations in input MAFs: 29413
-
After removing 257 invalidated mutations: 29156
-
After removing 200 noncoding mutations: 28956
-
After collapsing adjacent/redundant mutations: 21679
-
Number of mutations before filtering: 21679
-
After removing 199 mutations outside gene set: 21480
-
After removing 172 mutations outside category set: 21308
-
After removing 2 "impossible" mutations in
-
gene-patient-category bins of zero coverage: 20935
type | count |
---|---|
De_novo_Start_InFrame | 4 |
De_novo_Start_OutOfFrame | 30 |
Frame_Shift_Del | 151 |
Frame_Shift_Ins | 155 |
In_Frame_Del | 27 |
In_Frame_Ins | 7 |
Missense_Mutation | 14473 |
Nonsense_Mutation | 1779 |
Nonstop_Mutation | 6 |
Read-through | 10 |
Silent | 4628 |
Splice_Site | 38 |
Total | 21308 |
category | n | N | rate | rate_per_mb | relative_rate | exp_ns_s_ratio |
---|---|---|---|---|---|---|
*CpG->T | 4918 | 99631386 | 0.000049 | 49 | 5.4 | 2.1 |
*Cp(A/C/T)->mut | 6676 | 831878375 | 8e-06 | 8 | 0.89 | 3.3 |
A->mut | 2743 | 908606480 | 3e-06 | 3 | 0.33 | 3.9 |
*CpG->(G/A) | 135 | 99631386 | 1.4e-06 | 1.4 | 0.15 | 2.7 |
indel+null | 2050 | 1840116241 | 1.1e-06 | 1.1 | 0.12 | NaN |
double_null | 157 | 1840116241 | 8.5e-08 | 0.085 | 0.0094 | NaN |
Total | 16679 | 1840116241 | 9.1e-06 | 9.1 | 1 | 3.5 |
The x axis represents the samples. The y axis represents the exons, one row per exon, and they are sorted by average coverage across samples. For exons with exactly the same average coverage, they are sorted next by the %GC of the exon. (The secondary sort is especially useful for the zero-coverage exons at the bottom).
The mutation spectrum is depicted in the lego plots below in which the 96 possible mutation types are subdivided into six large blocks, color-coded to reflect the base substitution type. Each large block is further subdivided into the 16 possible pairs of 5' and 3' neighbors, as listed in the 4x4 trinucleotide context legend. The height of each block corresponds to the mutation frequency for that kind of mutation (counts of mutations normalized by the base coverage in a given bin). The shape of the spectrum is a signature for dominant mutational mechanisms in different tumor types.
Column Descriptions:
-
N = number of sequenced bases in this gene across the individual set
-
n = number of (nonsilent) mutations in this gene across the individual set
-
npat = number of patients (individuals) with at least one nonsilent mutation
-
nsite = number of unique sites having a non-silent mutation
-
nsil = number of silent mutations in this gene across the individual set
-
n1 = number of nonsilent mutations of type: *CpG->T
-
n2 = number of nonsilent mutations of type: *Cp(A/C/T)->mut
-
n3 = number of nonsilent mutations of type: A->mut
-
n4 = number of nonsilent mutations of type: *CpG->(G/A)
-
n5 = number of nonsilent mutations of type: indel+null
-
n6 = number of nonsilent mutations of type: double_null
-
p_classic = p-value for the observed amount of nonsilent mutations being elevated in this gene
-
p_ns_s = p-value for the observed nonsilent/silent ratio being elevated in this gene
-
p_cons = p-value for enrichment of mutations at evolutionarily most-conserved sites in gene
-
p_joint = p-value for clustering + conservation
-
p = p-value (overall)
-
q = q-value, False Discovery Rate (Benjamini-Hochberg procedure)
rank | gene | description | N | n | npat | nsite | nsil | n1 | n2 | n3 | n4 | n5 | n6 | p_classic | p_ns_s | p_clust | p_cons | p_joint | p | q |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | APC | adenomatous polyposis coli | 576224 | 66 | 57 | 56 | 0 | 1 | 4 | 4 | 0 | 39 | 18 | 3.89e-15 | 0.000014 | 0 | 0.93 | 0 | <1.00e-15 | <5.98e-12 |
2 | TP53 | tumor protein p53 | 79667 | 45 | 45 | 30 | 1 | 19 | 6 | 6 | 2 | 12 | 0 | 1.67e-15 | 0.00017 | 6e-07 | 0 | 0 | <1.00e-15 | <5.98e-12 |
3 | KRAS | v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog | 48604 | 38 | 38 | 8 | 0 | 0 | 36 | 1 | 0 | 1 | 0 | <1.00e-15 | 0.0034 | 0 | 0.002 | 0 | <1.00e-15 | <5.98e-12 |
4 | SMAD4 | SMAD family member 4 | 115264 | 8 | 8 | 6 | 0 | 2 | 3 | 3 | 0 | 0 | 0 | 8.11e-11 | 0.12 | 0.17 | 0.18 | 0.26 | 5.44e-10 | 2.44e-06 |
5 | KIAA1804 | 162266 | 11 | 9 | 9 | 0 | 7 | 3 | 1 | 0 | 0 | 0 | 1.25e-08 | 0.036 | 0.05 | 0.042 | 0.047 | 1.31e-08 | 4.71e-05 | |
6 | FBXW7 | F-box and WD repeat domain containing 7 | 177744 | 12 | 9 | 10 | 0 | 6 | 2 | 2 | 0 | 2 | 0 | 1.95e-08 | 0.075 | 0.077 | 0.063 | 0.057 | 2.40e-08 | 7.19e-05 |
7 | NRAS | neuroblastoma RAS viral (v-ras) oncogene homolog | 40433 | 5 | 5 | 4 | 0 | 0 | 3 | 2 | 0 | 0 | 0 | 1.06e-07 | 0.32 | 0.013 | 0.44 | 0.026 | 5.76e-08 | 0.000148 |
8 | TCF7L2 | transcription factor 7-like 2 (T-cell specific, HMG-box) | 119026 | 7 | 7 | 7 | 1 | 2 | 3 | 0 | 0 | 2 | 0 | 1.01e-07 | 0.26 | 0.11 | 0.072 | 0.077 | 1.53e-07 | 0.000343 |
9 | PIK3CA | phosphoinositide-3-kinase, catalytic, alpha polypeptide | 194975 | 7 | 7 | 7 | 1 | 1 | 3 | 3 | 0 | 0 | 0 | 2.12e-07 | 0.57 | 0.1 | 0.42 | 0.16 | 6.00e-07 | 0.00120 |
10 | OPCML | opioid binding protein/cell adhesion molecule-like | 73709 | 6 | 6 | 6 | 1 | 1 | 3 | 0 | 0 | 2 | 0 | 2.85e-07 | 0.32 | 0.49 | 0.47 | 0.68 | 3.18e-06 | 0.00570 |
11 | KRTAP5-5 | keratin associated protein 5-5 | 34487 | 2 | 2 | 1 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 2.10e-05 | 0.35 | 0.1 | 0.0062 | 0.013 | 4.51e-06 | 0.00735 |
12 | SMAD2 | SMAD family member 2 | 98964 | 5 | 5 | 5 | 0 | 0 | 3 | 1 | 0 | 1 | 0 | 2.17e-05 | 0.39 | 0.012 | 0.34 | 0.02 | 6.83e-06 | 0.0102 |
13 | SPATA8 | spermatogenesis associated 8 | 20140 | 3 | 3 | 3 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 4.19e-06 | 0.45 | 0.1 | 0.45 | 0.16 | 1.00e-05 | 0.0138 |
14 | ERBB2 | v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) | 227547 | 4 | 4 | 2 | 1 | 4 | 0 | 0 | 0 | 0 | 0 | 0.0238 | 0.54 | 0.00017 | 0.026 | 0.00013 | 4.23e-05 | 0.0542 |
15 | FAM123B | family with sequence similarity 123B | 190503 | 8 | 6 | 8 | 1 | 0 | 2 | 1 | 0 | 5 | 0 | 8.11e-05 | 0.58 | 0.07 | 0.64 | 0.14 | 0.000139 | 0.166 |
16 | ZIM3 | zinc finger, imprinted 3 | 98103 | 6 | 5 | 6 | 0 | 1 | 1 | 3 | 0 | 1 | 0 | 6.03e-05 | 0.21 | 0.44 | 0.098 | 0.22 | 0.000166 | 0.186 |
17 | PIK3R1 | phosphoinositide-3-kinase, regulatory subunit 1 (alpha) | 152490 | 5 | 4 | 5 | 0 | 2 | 0 | 0 | 0 | 1 | 2 | 0.000520 | 0.31 | 0.026 | 0.58 | 0.043 | 0.000260 | 0.275 |
18 | SGCB | sarcoglycan, beta (43kDa dystrophin-associated glycoprotein) | 64145 | 4 | 4 | 4 | 0 | 0 | 3 | 0 | 0 | 0 | 1 | 4.60e-05 | 0.51 | 0.32 | 0.73 | 0.7 | 0.000367 | 0.366 |
19 | LRRTM2 | leucine rich repeat transmembrane neuronal 2 | 59242 | 5 | 4 | 5 | 1 | 1 | 1 | 2 | 1 | 0 | 0 | 3.54e-05 | 0.58 | 0.98 | 0.8 | 1 | 0.000398 | 0.372 |
20 | OSBPL6 | oxysterol binding protein-like 6 | 208053 | 5 | 5 | 5 | 0 | 1 | 2 | 0 | 2 | 0 | 0 | 0.000295 | 0.25 | 0.22 | 0.069 | 0.13 | 0.000438 | 0.372 |
21 | CCBP2 | chemokine binding protein 2 | 79700 | 5 | 5 | 5 | 0 | 1 | 2 | 2 | 0 | 0 | 0 | 5.03e-05 | 0.23 | 0.78 | 0.32 | 0.84 | 0.000469 | 0.372 |
22 | CASP14 | caspase 14, apoptosis-related cysteine peptidase | 51900 | 5 | 4 | 4 | 0 | 4 | 1 | 0 | 0 | 0 | 0 | 0.000185 | 0.2 | 0.14 | 0.68 | 0.23 | 0.000476 | 0.372 |
23 | GFRA1 | GDNF family receptor alpha 1 | 86296 | 5 | 5 | 5 | 1 | 1 | 0 | 3 | 0 | 1 | 0 | 4.66e-05 | 0.55 | 0.62 | 0.96 | 0.94 | 0.000481 | 0.372 |
24 | EPYC | epiphycan | 67872 | 4 | 3 | 4 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0.000599 | 0.38 | 0.034 | 0.47 | 0.075 | 0.000497 | 0.372 |
25 | FAM133A | family with sequence similarity 133, member A | 38160 | 2 | 2 | 2 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0.00121 | 0.98 | 0.54 | 0.034 | 0.041 | 0.000547 | 0.392 |
26 | SLITRK1 | SLIT and NTRK-like family, member 1 | 134633 | 6 | 5 | 6 | 0 | 2 | 1 | 2 | 0 | 1 | 0 | 0.000291 | 0.18 | 0.13 | 0.58 | 0.2 | 0.000640 | 0.431 |
27 | MAP2K3 | mitogen-activated protein kinase kinase 3 | 67262 | 4 | 4 | 4 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 6.05e-05 | 0.3 | 0.77 | 0.62 | 1 | 0.000649 | 0.431 |
28 | PCDHA13 | protocadherin alpha 13 | 162857 | 8 | 6 | 8 | 0 | 3 | 1 | 2 | 1 | 1 | 0 | 9.77e-05 | 0.046 | 0.41 | 0.96 | 0.65 | 0.000676 | 0.433 |
29 | CACNG7 | calcium channel, voltage-dependent, gamma subunit 7 | 49136 | 3 | 3 | 3 | 0 | 2 | 0 | 0 | 1 | 0 | 0 | 0.000572 | 0.28 | 0.51 | 0.0087 | 0.13 | 0.000804 | 0.461 |
30 | CTNNB1 | catenin (cadherin-associated protein), beta 1, 88kDa | 162026 | 4 | 4 | 4 | 0 | 1 | 2 | 1 | 0 | 0 | 0 | 0.000828 | 0.42 | 0.074 | 0.35 | 0.094 | 0.000814 | 0.461 |
31 | FBXO15 | F-box protein 15 | 91945 | 3 | 3 | 3 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 0.00267 | 0.28 | 0.008 | 0.38 | 0.03 | 0.000830 | 0.461 |
32 | PRIM2 | primase, DNA, polypeptide 2 (58kDa) | 57190 | 3 | 3 | 3 | 1 | 0 | 0 | 0 | 0 | 3 | 0 | 0.000842 | 0.97 | NaN | NaN | NaN | 0.000842 | 0.461 |
33 | EDNRB | endothelin receptor type B | 89905 | 5 | 4 | 5 | 1 | 0 | 2 | 3 | 0 | 0 | 0 | 0.000440 | 0.62 | 0.12 | 0.32 | 0.18 | 0.000848 | 0.461 |
34 | CFHR5 | complement factor H-related 5 | 116845 | 3 | 3 | 3 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0.000855 | 0.52 | 0.23 | 0.061 | 0.1 | 0.000890 | 0.470 |
35 | ELF3 | E74-like factor 3 (ets domain transcription factor, epithelial-specific ) | 71547 | 3 | 3 | 3 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0.000871 | 0.75 | 0.048 | 0.33 | 0.1 | 0.000917 | 0.470 |
In this analysis, COSMIC is used as a filter to increase power by restricting the territory of each gene. Cosmic version: v48.
rank | gene | description | n | cos | n_cos | N_cos | cos_ev | p | q |
---|---|---|---|---|---|---|---|---|---|
1 | KRAS | v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog | 38 | 52 | 37 | 3588 | 363199 | 1.8e-13 | 8e-10 |
2 | TP53 | tumor protein p53 | 45 | 824 | 45 | 56856 | 17987 | 1.7e-12 | 2.6e-09 |
3 | APC | adenomatous polyposis coli | 66 | 839 | 50 | 57891 | 1048 | 1.7e-12 | 2.6e-09 |
4 | NRAS | neuroblastoma RAS viral (v-ras) oncogene homolog | 5 | 33 | 5 | 2277 | 5755 | 3.1e-11 | 3.5e-08 |
5 | FBXW7 | F-box and WD repeat domain containing 7 | 12 | 91 | 6 | 6279 | 329 | 4.5e-11 | 4.1e-08 |
6 | SMAD4 | SMAD family member 4 | 8 | 159 | 6 | 10971 | 39 | 1.2e-09 | 9.3e-07 |
7 | KRTAP5-5 | keratin associated protein 5-5 | 2 | 1 | 2 | 69 | 2 | 1.9e-07 | 0.00012 |
8 | ERBB2 | v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) | 4 | 42 | 3 | 2898 | 6 | 3e-06 | 0.0017 |
9 | PIK3CA | phosphoinositide-3-kinase, catalytic, alpha polypeptide | 7 | 220 | 4 | 15180 | 1382 | 0.000013 | 0.0067 |
10 | LRP1B | low density lipoprotein-related protein 1B (deleted in tumors) | 20 | 18 | 2 | 1242 | 2 | 0.000063 | 0.028 |
Note:
n - number of (nonsilent) mutations in this gene across the individual set.
cos = number of unique mutated sites in this gene in COSMIC
n_cos = overlap between n and cos.
N_cos = number of individuals times cos.
cos_ev = total evidence: number of reports in COSMIC for mutations seen in this gene.
p = p-value for seeing the observed amount of overlap in this gene)
q = q-value, False Discovery Rate (Benjamini-Hochberg procedure)
num | gene | desc | n | mindist | nmuts0 | nmuts3 | nmuts12 | npairs0 | npairs3 | npairs12 |
---|---|---|---|---|---|---|---|---|---|---|
3873 | KRAS | v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog | 38 | 0 | 278 | 416 | 445 | 278 | 416 | 445 |
7548 | TP53 | tumor protein p53 | 45 | 0 | 37 | 61 | 105 | 37 | 61 | 105 |
392 | APC | adenomatous polyposis coli | 66 | 0 | 11 | 21 | 47 | 11 | 21 | 47 |
2614 | FBXW7 | F-box and WD repeat domain containing 7 | 12 | 0 | 6 | 6 | 6 | 6 | 6 | 6 |
4876 | NRAS | neuroblastoma RAS viral (v-ras) oncogene homolog | 5 | 0 | 6 | 6 | 6 | 6 | 6 | 6 |
6842 | SMAD4 | SMAD family member 4 | 8 | 0 | 4 | 4 | 6 | 4 | 4 | 6 |
2360 | ERBB2 | v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) | 4 | 0 | 3 | 3 | 3 | 3 | 3 | 3 |
3783 | KIAA1804 | 11 | 0 | 2 | 6 | 7 | 2 | 6 | 7 | |
3466 | IL1RAPL2 | interleukin 1 receptor accessory protein-like 2 | 5 | 0 | 1 | 3 | 3 | 1 | 3 | 3 |
2082 | DNAH5 | dynein, axonemal, heavy chain 5 | 19 | 0 | 1 | 2 | 2 | 1 | 2 | 2 |
Note:
n - number of mutations in this gene in the individual set.
mindist - distance (in aa) between closest pair of mutations in this gene
npairs3 - how many pairs of mutations are within 3 aa of each other.
npairs12 - how many pairs of mutations are within 12 aa of each other.
rank | geneset | description | genes | N_genes | mut_tally | N | n | npat | nsite | nsil | n1 | n2 | n3 | n4 | n5 | n6 | p_ns_s | p | q |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | ST_ADRENERGIC | Adrenergic receptors respond to epinephrine and norepinephrine signaling. | AKT1, APC, AR, ASAH1, BF, BRAF, CAMP, CCL13, CCL15, CCL16, DAG1, EGFR, GAS, GNA11, GNA15, GNAI1, GNAQ, ITPKA, ITPKB, ITPR1, ITPR2, ITPR3, KCNJ3, KCNJ5, KCNJ9, MAPK1, MAPK10, MAPK14, PHKA2, PIK3CA, PIK3CD, PIK3R1, PITX2, PTX1, PTX3, RAF1, SRC | 34 | APC(66), AR(2), BRAF(2), DAG1(1), EGFR(1), GNAI1(1), GNAQ(1), ITPR1(8), ITPR2(6), ITPR3(1), KCNJ5(1), KCNJ9(1), MAPK10(4), PHKA2(1), PIK3CA(7), PIK3CD(1), PIK3R1(5), RAF1(2) | 5018319 | 111 | 60 | 101 | 7 | 18 | 15 | 11 | 0 | 46 | 21 | 4.9e-08 | <1.00e-15 | <1.07e-13 |
2 | P53HYPOXIAPATHWAY | Hypoxia induces p53 accumulation and consequent apoptosis with p53-mediated cell cycle arrest, which is present under conditions of DNA damage. | ABCB1, AKT1, ATM, BAX, CDKN1A, CPB2, CSNK1A1, CSNK1D, FHL2, GADD45A, HIC1, HIF1A, HSPA1A, HSPCA, IGFBP3, MAPK8, MDM2, NFKBIB, NQO1, TP53 | 18 | ABCB1(5), ATM(10), CPB2(1), CSNK1D(1), FHL2(1), HIF1A(2), IGFBP3(2), MAPK8(5), TP53(45) | 2001688 | 72 | 50 | 57 | 4 | 26 | 18 | 9 | 3 | 15 | 1 | 0.000018 | <1.00e-15 | <1.07e-13 |
3 | PLK3PATHWAY | Active Plk3 phosphorylates CDC25c, blocking the G2/M transition, and phosphorylates p53 to induce apoptosis. | ATM, ATR, CDC25C, CHEK1, CHEK2, CNK, TP53, YWHAH | 7 | ATM(10), ATR(4), CDC25C(1), TP53(45), YWHAH(1) | 1621418 | 61 | 49 | 46 | 6 | 22 | 16 | 7 | 2 | 13 | 1 | 0.015 | <1.00e-15 | <1.07e-13 |
4 | TELPATHWAY | Telomerase is a ribonucleotide protein that adds telomeric repeats to the 3' ends of chromosomes. | AKT1, BCL2, EGFR, G22P1, HSPCA, IGF1R, KRAS2, MYC, POLR2A, PPP2CA, PRKCA, RB1, TEP1, TERF1, TERT, TNKS, TP53, XRCC5 | 15 | EGFR(1), IGF1R(1), PRKCA(2), RB1(3), TERF1(1), TP53(45), XRCC5(2) | 2767314 | 55 | 48 | 40 | 6 | 22 | 9 | 9 | 2 | 13 | 0 | 0.0014 | <1.00e-15 | <1.07e-13 |
5 | TGFBPATHWAY | The TGF-beta receptor responds to ligand binding by activating the SMAD family of transcriptional regulations, commonly blocking cell growth. | APC, CDH1, CREBBP, EP300, MADH2, MADH3, MADH4, MADH7, MADHIP, MAP2K1, MAP3K7, MAP3K7IP1, MAPK3, SKIL, TGFB1, TGFB2, TGFB3, TGFBR1, TGFBR2 | 13 | APC(66), CDH1(1), CREBBP(4), EP300(2), MAP2K1(1), MAP3K7(2), MAPK3(1), SKIL(1), TGFB2(4), TGFBR1(3) | 2554178 | 85 | 57 | 75 | 4 | 5 | 10 | 8 | 0 | 44 | 18 | 5.2e-06 | 1.11e-15 | 1.07e-13 |
6 | PITX2PATHWAY | The bicoid-related transcription factor Pitx2 is activated by Wnt binding to the Frizzled receptor and induces tissue-specific cell proliferation. | APC, AXIN1, CREBBP, CTNNB1, DVL1, EP300, FZD1, GSK3B, HDAC1, HTATIP, LDB1, LEF1, PITX2, PPARBP, TRRAP, WNT1 | 13 | APC(66), AXIN1(1), CREBBP(4), CTNNB1(4), EP300(2), FZD1(1), GSK3B(1), LDB1(2), TRRAP(4) | 3136901 | 85 | 58 | 75 | 4 | 8 | 12 | 6 | 0 | 41 | 18 | 1e-06 | 1.22e-15 | 1.07e-13 |
7 | WNTPATHWAY | The Wnt glycoprotein binds to membrane-bound receptors such as Frizzled to activate a number of signaling pathways, including that of beta-catenin. | APC, AXIN1, BTRC, CCND1, CREBBP, CSNK1A1, CSNK1D, CSNK2A1, CTBP1, CTNNB1, DVL1, FRAT1, FZD1, GSK3B, HDAC1, MADH4, MAP3K7, MAP3K7IP1, MYC, NLK, PPARD, PPP2CA, TCF1, TLE1, WIF1, WNT1 | 21 | APC(66), AXIN1(1), BTRC(3), CREBBP(4), CSNK1D(1), CTNNB1(4), FZD1(1), GSK3B(1), MAP3K7(2), PPARD(1) | 2701685 | 84 | 58 | 74 | 4 | 8 | 9 | 8 | 0 | 41 | 18 | 1.8e-06 | 1.22e-15 | 1.07e-13 |
8 | WNT_SIGNALING | Wnt signaling genes | APC, ARHA, AXIN1, C2orf31, CCND1, CCND2, CCND3, CSNK1E, CSNK1E, LOC400927, CTNNB1, DIPA, DVL1, DVL2, DVL3, FBXW2, FOSL1, FRAT1, FZD1, FZD10, FZD2, FZD3, FZD5, FZD6, FZD7, FZD8, FZD9, GSK3B, JUN, LDLR, MAPK10, MAPK9, MYC, PAFAH1B1, PLAU, PPP2R5C, PPP2R5E, PRKCA, PRKCB1, PRKCD, PRKCE, PRKCG, PRKCH, PRKCI, PRKCM, PRKCQ, PRKCZ, PRKD1, RAC1, RHOA, SFRP4, TCF7, WNT1, WNT10A, WNT10B, WNT11, WNT16, WNT2, WNT2B, WNT3, WNT4, WNT5A, WNT5B, WNT6, WNT7A, WNT7B | 57 | APC(66), AXIN1(1), CTNNB1(4), DVL2(1), DVL3(2), FBXW2(1), FZD1(1), FZD10(2), FZD3(3), FZD6(3), GSK3B(1), LDLR(1), MAPK10(4), MAPK9(2), PLAU(1), PPP2R5C(1), PRKCA(2), PRKCE(2), PRKCG(2), PRKCH(1), PRKCQ(1), PRKD1(5), RHOA(1), SFRP4(1), TCF7(3), WNT10B(1), WNT2(1), WNT2B(2), WNT6(1) | 5514820 | 117 | 58 | 107 | 13 | 15 | 27 | 8 | 0 | 49 | 18 | 6.7e-06 | 1.44e-15 | 1.09e-13 |
9 | P53PATHWAY | p53 induces cell cycle arrest or apoptosis under conditions of DNA damage. | APAF1, ATM, BAX, BCL2, CCND1, CCNE1, CDK2, CDK4, CDKN1A, E2F1, GADD45A, MDM2, PCNA, RB1, TIMP3, TP53 | 16 | APAF1(1), ATM(10), CDK4(1), PCNA(1), RB1(3), TIMP3(1), TP53(45) | 1820960 | 62 | 50 | 47 | 6 | 21 | 14 | 9 | 2 | 15 | 1 | 0.002 | 1.67e-15 | 1.09e-13 |
10 | ALKPATHWAY | Activin receptor-like kinase 3 (ALK3) is required during gestation for cardiac muscle development. | ACVR1, APC, ATF2, AXIN1, BMP10, BMP2, BMP4, BMP5, BMP7, BMPR1A, BMPR2, CHRD, CTNNB1, DVL1, FZD1, GATA4, GSK3B, MADH1, MADH4, MADH5, MADH6, MAP3K7, MEF2C, MYL2, NKX2-5, NOG, NPPA, NPPB, RFC1, TCF1, TGFB1, TGFB2, TGFB3, TGFBR1, TGFBR2, TGFBR3, WNT1 | 31 | ACVR1(1), APC(66), ATF2(1), AXIN1(1), BMP10(1), BMP2(1), BMP4(1), BMP5(1), BMP7(1), BMPR2(3), CTNNB1(4), FZD1(1), GSK3B(1), MAP3K7(2), MEF2C(2), NPPB(1), RFC1(4), TGFB2(4), TGFBR1(3), TGFBR3(3) | 3414527 | 102 | 59 | 92 | 3 | 13 | 19 | 9 | 0 | 43 | 18 | 6.1e-09 | 1.78e-15 | 1.09e-13 |
rank | geneset | description | genes | N_genes | mut_tally | N | n | npat | nsite | nsil | n1 | n2 | n3 | n4 | n5 | n6 | p_ns_s | p | q |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | ERBB4PATHWAY | ErbB4 (aka HER4) is a receptor tyrosine kinase that binds neuregulins as well as members of the EGF family, which also target EGF receptors. | ADAM17, ERBB4, NRG2, NRG3, PRKCA, PRKCB1, PSEN1 | 6 | ADAM17(1), ERBB4(5), NRG2(2), NRG3(4), PRKCA(2) | 908762 | 14 | 9 | 14 | 1 | 4 | 5 | 1 | 1 | 3 | 0 | 0.073 | 0.0014 | 0.9 |
2 | GSPATHWAY | Activated G-protein coupled receptors stimulate cAMP production and thus activate protein kinase A, involved in a number of signal transduction pathways. | ADCY1, GNAS, GNB1, GNGT1, PRKACA, PRKAR1A | 6 | ADCY1(4), GNGT1(1), PRKACA(1), PRKAR1A(4) | 607553 | 10 | 8 | 10 | 1 | 3 | 4 | 1 | 0 | 2 | 0 | 0.2 | 0.0071 | 1 |
3 | HSA00472_D_ARGININE_AND_D_ORNITHINE_METABOLISM | Genes involved in D-arginine and D-ornithine metabolism | DAO | 1 | DAO(4) | 73821 | 4 | 3 | 4 | 0 | 3 | 1 | 0 | 0 | 0 | 0 | 0.28 | 0.012 | 1 |
4 | C21_STEROID_HORMONE_METABOLISM | AKR1C4, AKR1D1, CYP11A1, CYP11B1, CYP11B2, CYP17A1, CYP21A2, HSD11B1, HSD11B2, HSD3B1, HSD3B2 | 11 | AKR1C4(1), AKR1D1(1), CYP11A1(2), CYP11B1(4), CYP21A2(1), HSD3B1(1), HSD3B2(1) | 837086 | 11 | 10 | 11 | 2 | 3 | 5 | 1 | 0 | 2 | 0 | 0.31 | 0.017 | 1 | |
5 | HSA00140_C21_STEROID_HORMONE_METABOLISM | Genes involved in C21-steroid hormone metabolism | AKR1C4, AKR1D1, CYP11A1, CYP11B1, CYP11B2, CYP17A1, CYP21A2, HSD11B1, HSD11B2, HSD3B1, HSD3B2 | 11 | AKR1C4(1), AKR1D1(1), CYP11A1(2), CYP11B1(4), CYP21A2(1), HSD3B1(1), HSD3B2(1) | 837086 | 11 | 10 | 11 | 2 | 3 | 5 | 1 | 0 | 2 | 0 | 0.31 | 0.017 | 1 |
6 | NUCLEOTIDE_GPCRS | ADORA1, ADORA2A, ADORA2B, ADORA3, GPR23, LTB4R, P2RY1, P2RY2, P2RY5, P2RY6 | 8 | ADORA1(3), ADORA2A(2), LTB4R(1), P2RY1(3), P2RY2(1), P2RY6(1) | 524943 | 11 | 6 | 11 | 0 | 5 | 5 | 1 | 0 | 0 | 0 | 0.014 | 0.032 | 1 | |
7 | NKCELLSPATHWAY | Natural killer (NK) lymphocytes are inhibited by MHC and activated by surface glycoproteins on tumor or virus-infected cells, which undergo perforin-mediated lysis. | B2M, HLA-A, IL18, ITGB1, KLRC1, KLRC2, KLRC3, KLRC4, KLRD1, LAT, MAP2K1, MAPK3, PAK1, PIK3CA, PIK3R1, PTK2B, PTPN6, RAC1, SYK, VAV1 | 19 | B2M(3), HLA-A(2), KLRC3(1), LAT(1), MAP2K1(1), MAPK3(1), PAK1(1), PIK3R1(5), SYK(3), VAV1(2) | 1594854 | 20 | 8 | 20 | 1 | 4 | 5 | 4 | 0 | 4 | 3 | 0.034 | 0.035 | 1 |
8 | PS1PATHWAY | Presenilin is required for gamma-secretase activity to activate Notch signaling; presenilin also inhibits beta-catenin in the Wnt/Frizzled pathway. | ADAM17, APC, AXIN1, BTRC, CTNNB1, DLL1, DVL1, FZD1, GSK3B, NOTCH1, PSEN1, RBPSUH, TCF1, WNT1 | 10 | ADAM17(1), AXIN1(1), BTRC(3), CTNNB1(4), DLL1(3), FZD1(1), GSK3B(1) | 1369199 | 14 | 9 | 14 | 1 | 5 | 4 | 2 | 0 | 3 | 0 | 0.041 | 0.05 | 1 |
9 | HSA00643_STYRENE_DEGRADATION | Genes involved in styrene degradation | FAH, GSTZ1, HGD | 3 | FAH(1), HGD(1) | 179749 | 2 | 2 | 2 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0.78 | 0.073 | 1 |
10 | PTENPATHWAY | PTEN suppresses AKT-induced cell proliferation and antagonizes the action of PI3K. | AKT1, BCAR1, CDKN1B, FOXO3A, GRB2, ILK, ITGB1, MAPK1, MAPK3, PDK2, PDPK1, PIK3CA, PIK3R1, PTEN, PTK2, SHC1, SOS1, TNFSF6 | 15 | CDKN1B(2), GRB2(1), MAPK3(1), PDK2(1), PIK3R1(5), PTEN(4), SOS1(2) | 1658685 | 16 | 7 | 16 | 1 | 3 | 4 | 2 | 0 | 5 | 2 | 0.073 | 0.089 | 1 |
In brief, we tabulate the number of mutations and the number of covered bases for each gene. The counts are broken down by mutation context category: four context categories that are discovered by MutSig, and one for indel and 'null' mutations, which include indels, nonsense mutations, splice-site mutations, and non-stop (read-through) mutations. For each gene, we calculate the probability of seeing the observed constellation of mutations, i.e. the product P1 x P2 x ... x Pm, or a more extreme one, given the background mutation rates calculated across the dataset. [1]
In addition to the links below, the full results of the analysis summarized in this report can also be downloaded programmatically using firehose_get, or interactively from either the Broad GDAC website or TCGA Data Coordination Center Portal.